Congratulations to Dr. Jaime Hyman, Associate Professor of Anesthesiology, Division Chief of Ambulatory, Yale School of Medicine, who has been highlighted as the November / December "Featured Member" on the MPOG (Multicenter Perioperative Outcomes Group) website. This recognition marks her leadership of Yale and YNHHS, with departmental support from Chair Lisa Leffert, to participate in the $20 million PCORI-funded Trajectories of Recovery after Intravenous propofol vs. inhaled VolatilE anesthesia (THRIVE) prospective, randomized clinical trial. THRIVE aims to randomize 12,500 patients across over 20 leading anesthesiology departments to understand patients’ self-reported quality of recovery following inhalation anesthesia vs. total intravenous anesthesia.
MPOG, which serves as the data coordinating center for the trial, is a consortium of over 60 anesthesiology departments across three countries based out of University of Michigan that promotes safe and evidence-based perioperative care for all patients through research, education, and quality improvement.
As the featured member, Dr. Hyman’s participation in THRIVE seeks to investigate one of the most fundamental questions regarding modern anesthesia care: namely, which type of general anesthesia - between intravenous anesthetics such as propofol or inhaled volatile anesthetics such as sevoflurane - provides patients with a better trajectory of recovery after surgery. The project is expected to last 6.5 years, and Dr. Hyman’s Yale team is presently a leading site in terms of patient recruitment with near 100% treatment adherence and patient follow-up.
Of note, the Yale Department of Anesthesiology’s participation in this clinical trial was enabled by 1. Yale IT leadership from Prem Thomas, Allen Hsiao, and Robert Schonberger in becoming the first EPIC site to join MPOG in 2014, as well as 2. the close collaboration of David Coleman, head of YCCI, who was instrumental in bringing Yale’s IRB policies into concordance with best practices that allow for Yale anesthesiologists to participate independently in recruiting diverse participants into pivotal clinical trials rather than having to rely on personnel from other departments.
By comparing propofol TIVA and inhaled volatile anesthesia, the THRIVE team hopes to improve patient outcomes, by determining whether one of the two tested general anesthesia techniques benefits quality of recovery and functional status, while assessing any impact on risk of delirium, intraoperative awareness with recall, kidney injury, respiratory failure and mortality.
Thanks to Dr. Hyman and her team, Yale has gained notoriety as a top site for clinical trial recruitment both for THRIVE and for future clinical trials. Please join us in congratulating Dr. Hyman and the Department of Anesthesiology on this tremendous achievement!